Tag: 170911-92-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170911-92-9,tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Example 202 [7-(1-Ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]-(4-piperazin-1-yl-phenyl)-amine To a mixture of 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (133 mg, 0.48 mmol) and sodium tert-butoxide (57.6 mg, 0.6 mmol) in 1,4-dioxane (0.5 mL) is added a solution of 2-chloro-7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidine (90 mg, 0.4 mmol) in 1,4-dioxane (1.0 mL), Pd2(dba)3 (18.3 mg, 0.02 mmol) and BINAP (25 mg, 0.04 mmol). The mixture is degassed, and heated at 100 C. for 3 h. The mixture is cooled to room temperature, diluted with EtOAc, and filtered through celite. The filtrate is concentrated under reduced pressure. The residue is purified by flash chromatography (SiO2, EtOAc_Hexane=1:1) to give 167 mg of 4-{4-[7-(1-ethyl-propyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester as a pale yellow solid.

170911-92-9, 170911-92-9 tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate 11011301, apiperazines compound, is more and more widely used in various.

Reference£º
Patent; Astex Therapeutics Ltd.; US2009/318441; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170911-92-9,tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

A mixture of YL7-102 (8c, Scheme 3) (0.308 g, 0.8 mmol) and tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate (0.222 g, 0.8 mmol) in 2-propanol (4 mL) was heated at80 C in a sealed tube for 5 h. The resulting precipitate was filtered upon cooling, and washed with 2-propanol (2 mL x 3), then dried under high vacuum to afford the title compound as a light green solid (0.440 g, 83%). Mp.: 184-186 C; HPLC 99.8% (tR = 5.23 mm, 70% CH3OH in 0.1% TFA water, 20 mm); ?H NMR (400 MHz, DMSO-d6): oe 10.26 (brs, 1H disappear on D20 shake), 10.12 (brs, 1H disappear on D20 shake), 9.31 (brs, 1H disappear on D20 shake), 8.71 (s, 1H),7.51-7.33 (m, 4H), 7.02 (appd, J 6.0 Hz, 2H), 4.05-3.98 (m, 1H), 3.75-3.70 (m, 1H overlapping with water peak), 3.63-3.57 (m, 1H overlapping with water peak), 3.47-3.42 (m, 6H), 3.10 (brs, 4H), 1.96-1.88 (m, 1H), 1.83-1.76 (m, 2H), 1.56-1.48 (m, 1H), 1.40 (s, 9H); ?9F NMR (376 MHz, DMSO-d6): oe -116.16- -116.20 (m); LC-MS (ESI+) m/z 626.25; (M+H) HRMS (ESI+) m/z calculated for C3,H38C1FN704 (M+H) 626.2652, found 626.2651.

As the paragraph descriping shows that 170911-92-9 is playing an increasingly important role.

Reference£º
Patent; H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.; MAHAJAN, Nupam, P.; MAHAJAN, Kiran, N.; LAWRENCE, Nicholas, J.; LAWRENCE, Harshani, R.; WO2015/21149; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170911-92-9,tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

The 4- chloropyrimidine SG2-022 was prepared using the previously reported method.1 A solution of 2,4-dichloro-5-trifluoromethylpyrimidine (120 mg, 0.550 mmol) in i-BuOH/DCM (1:1, 4 mL) was cooled to 0 C. Zinc chloride (1 M in diethyl ether, 0.633 mL, 0.633 mmol) was added dropwise over 10 minutes at 0 C and the solution stirred at the same temperature for 30 minutes. A solution of iPatent; H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC.; SCHOeNBRUNN, Ernst; LAWRENCE, Nicholas J.; LAWRENCE, Harshani R.; (293 pag.)WO2017/66428; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics